Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company generates news across medical device innovation, regulatory approvals, manufacturing expansions, and healthcare industry developments. As one of the world's largest medical technology manufacturers producing tens of billions of devices annually, BD's announcements often impact healthcare supply chains, public health initiatives, and clinical practice standards.
News coverage for BD typically encompasses product launches of safety-engineered medical devices, FDA clearances for new diagnostic instruments and drug delivery systems, and manufacturing capacity announcements that affect global medical supply availability. The company's role as a major supplier of syringes, needles, IV catheters, and diagnostic equipment means its production decisions can influence healthcare delivery capabilities, particularly during public health emergencies and vaccination campaigns.
Earnings reports reveal performance across BD's three business segments: Medical, Life Sciences, and Interventional. These disclosures provide insight into healthcare spending trends, adoption rates for new medical technologies, and geographic market dynamics across developed and emerging healthcare markets. Regulatory developments, including FDA warning letters, device recalls, or quality system issues, also generate significant news given the company's broad product portfolio and global manufacturing footprint.
Corporate developments such as acquisitions of medical device companies, divestitures of business units, strategic partnerships with pharmaceutical manufacturers, and manufacturing investments shape BD's competitive position. The company's interactions with group purchasing organizations, healthcare systems, and regulatory agencies produce news relevant to understanding healthcare economics and medical device industry dynamics.
Track BD news to monitor developments in medical device innovation, healthcare supply chain updates, regulatory compliance matters, and business performance across the company's medical technology portfolio. Understanding BD's announcements provides context on trends in hospital supply management, clinical diagnostics, and medication delivery technologies.
BD (Becton, Dickinson and Company) has launched the BD Veritor™ At-Home COVID-19 Test, now available through Everly Health and Southeastern Grocers, including Fresco y Más, Harveys Supermarket, and Winn-Dixie. The test is unique as it utilizes a smartphone app to interpret results, ensuring accuracy without human error. BD emphasizes the test's importance for community safety amidst rising COVID-19 cases, especially during the holiday season. The test is available online and in-store, enabling broad access for consumers.
BD (Becton, Dickinson and Company) announced the formation of a nine-person board of directors for Embecta Corp., which will hold BD's Diabetes Care business after the planned spinoff. The board will be led by David F. Melcher and include notable members such as Claire Pomeroy and Christopher R. Reidy. Devdatt Kurdikar will serve as CEO of Embecta. The spinoff is expected to be completed in Q2 2022, pending regulatory approvals. The governance structure includes various committees, and directors will serve staggered terms.
BD (Becton, Dickinson and Company) has successfully acquired Scanwell Health Inc., a pioneer in smartphone-enabled at-home medical testing. The acquisition aims to enhance BD's digital capabilities for at-home diagnostics, including COVID-19 and other infectious diseases. The BD Veritor™ At-Home COVID-19 Test leverages smartphone technology for accurate result interpretation. Although transaction details were not disclosed, it is anticipated to have an immaterial impact on BD's fiscal 2022 financials. This move underscores BD's commitment to innovative health solutions.
BD (Becton, Dickinson and Company) (NYSE: BDX) has expanded its BD COR™ System with the introduction of the MX instrument, designed for high-throughput molecular testing for infectious diseases, including a new CE-marked assay for sexually transmitted infections. The MX instrument, part of a modular system alongside the PX and GX instruments, can process 1,700 specimens and deliver up to 1,000 results in 24 hours, enhancing laboratory efficiency. The platform automates testing workflows, improving diagnostics for women's health and STIs.
BioGX announced that its SARS-CoV-2 diagnostic portfolio can detect the Omicron variant (B.1.1.529). The surveillance program includes in-silico analyses confirming detection across all variants of interest. BioGX's COVID-19 RT-PCR tests are compatible with several real-time PCR platforms, notably the Xfree COVID-19 Direct RT-PCR, which is FDA authorized for multiple specimen types. This test offers extraction-free options, enhancing workflow efficiency. BioGX operates under ISO 13485 standards, providing over 60 multiplex real-time PCR products worldwide.
BD (Becton, Dickinson and Company) announced that the new name for its upcoming spinoff of the Diabetes Care business will be embecta. This independent, publicly-traded company aims to empower those living with diabetes while maintaining a connection to BD's legacy. The spinoff is expected to finalize in the second quarter of 2022. Devdatt Kurdikar will serve as CEO, leading a diverse team focused on innovation and improvement in diabetes care products. The name reflects the company's commitment and heritage, aiming to enhance the quality of life for diabetes patients globally.
BD (Becton, Dickinson and Company) has acquired Venclose, Inc., a leader in treatments for chronic venous insufficiency (CVI). This acquisition enhances BD's portfolio of venous disease technologies, leveraging Venclose's innovative Radio Frequency (RF) ablation system that is designed for efficiency and versatility. CVI affects up to 40% of women and 17% of men in the U.S. The dual heating length of the Venclose System allows multiple vein segments to be ablated with one catheter, potentially reducing post-operative pain for patients. The financial impact of the deal is expected to be immaterial for BD's fiscal 2022.
BD (Becton, Dickinson and Company) (NYSE: BDX) issued a statement confirming the effectiveness of its rapid antigen and PCR tests for detecting the COVID-19 Omicron variant. Conducting an analysis based on genome sequences up to Nov. 29, 2021, BD remains confident that its testing methods will identify this new variant. To date, the company has evaluated over 3.5 million SARS-CoV-2 genomes and reported no undetectable variants. BD emphasizes the importance of reliable testing in combating COVID-19's spread and will continue rigorous performance monitoring.
BD (Becton, Dickinson and Company) has appointed Dr. Joseph M. Smith as the new senior vice president and chief scientific officer, effective November 29, 2021. In this role, Smith will oversee external innovation and the technology roadmap for BD, focusing on the future of healthcare, including smart connected care and chronic disease management. He has over 30 years of experience in digital health, previously serving as CEO of Digital Health Corp. Smith holds multiple advanced degrees and has authored numerous publications while holding several patents.
FAQ
What is the current stock price of Becton Dickinson & Co (BDX)?
What is the market cap of Becton Dickinson & Co (BDX)?
